Please login to the form below

Not currently logged in
Email:
Password:

GSK buys Shenzhen Neptunus stake

GSK is set to become the sole owner of joint venture company Shenzhen GSK-Neptunus Biologicals

GlaxoSmithKline (GSK) has entered into an agreement to acquire the remaining 51 per cent stake of Shenzhen Neptunus Interlong Bio-Technique Co in the joint venture (JV) company, Shenzhen GSK-Neptunus Biologicals Co (GSKNB), for £24m ($39m) in cash. 

Established in June 2009, the GSKNB alliance focuses on the development and manufacture of seasonal and pandemic influenza vaccines for China, Hong Kong and Macau. GSK increased its share from 40 per cent to 49 per cent in August 2010.

Jean Stephenne, chairman and president GSK Biologicals, said: "The decision to acquire the remaining equity interest in GSKNB reflects the importance GSK places in expanding our product offering in China and making new vaccines available to improve public health in this fast growing emerging market. GSKNB employees have made good progress preparing the site for the production of influenza vaccines and we look forward to continuing this work."

After approval of this agreement by the Peoples Republic of China's authorities, GSK will become the sole owner of GSKNB. 

14th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics